文献速递浆细胞疾病造血干细胞移植与细胞治疗

FcεRIγ阴性NK细胞在多发性骨髓瘤中持久存在并增强治疗性单克隆抗体疗效

FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma.
PubMed 文献 · Blood Adv · 2021-01-01

本研究探讨缺乏FcεRIγ表达的NK细胞亚群(g-NK细胞)增强多发性骨髓瘤(MM)治疗性单克隆抗体(mAb)疗效的能力。体外实验显示g-NK细胞联合达雷妥尤单抗或埃罗妥珠单抗的抗骨髓瘤细胞毒性显著优于常规NK细胞(约6倍;P < .001)。在肿瘤初治小鼠模型中,g-NK细胞在血液和脾脏中的持久性超过常规NK细胞10倍以上(31天内,P < .001),且达雷妥尤单抗联合g-NK细胞导致>99.9%的肿瘤减少(P < .001),7只小鼠中5只骨髓瘤负荷完全消除。

要点

  • g-NK细胞联合达雷妥尤单抗或埃罗妥珠单抗的体外抗骨髓瘤毒性约为常规NK细胞的6倍(P < .001)。
  • g-NK细胞表面CD38和SLAMF7表达极低,可减少治疗性单抗对效应细胞的误伤。
  • 小鼠模型中g-NK细胞持久性超常规NK细胞10倍以上,联合达雷妥尤单抗使7只中5只肿瘤完全消除。

核心结论

  • g-NK细胞能增强治疗性mAb对MM的疗效,并克服现有现货NK细胞疗法的局限性,无需辐照或基因工程改造。

研究设计与样本

  • 体外实验比较g-NK与常规NK细胞联合达雷妥尤单抗或埃罗妥珠单抗的抗骨髓瘤细胞毒性。
  • 采用肿瘤初治小鼠模型评估g-NK细胞体内持久性及联合达雷妥尤单抗的疗效。

主要发现

  • 体外联合达雷妥尤单抗或埃罗妥珠单抗时,g-NK细胞抗骨髓瘤细胞毒性约为常规NK细胞的6倍(P < .001)。
  • g-NK细胞天然表面CD38和SLAMF7表达极低,降低了治疗性单抗的误伤发生率。
  • 小鼠模型中g-NK细胞在血液和脾脏的持久性在31天内超过常规NK细胞10倍以上(P < .001)。
  • 达雷妥尤单抗联合g-NK细胞导致>99.9%的肿瘤减少(流式细胞术分析),优于联合常规NK细胞(P < .001)。
  • 达雷妥尤单抗联合g-NK细胞使7只小鼠中5只骨髓瘤负荷完全消除。

临床怎么用

  • g-NK细胞有望作为增强MM治疗性mAb疗效的现货细胞疗法,且无需辐照或基因改造。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Monoclonal antibodies (mAbs) are a central component of therapy for hematologic malignancies. Widely used mAb agents in multiple myeloma (MM) include daratumumab and elotuzumab. However, not all patients respond to these agents, and resistance is a significant clinical issue. A recently discovered subset of human natural killer (NK) cells lacking expression of FcεRIγ (g-NK cells) was found to have a multifold increase in antibody-dependent effector functions after CD16 crosslinking. In this study, we tested the capacity of g-NK cells to enhance the efficacy of therapeutic mAbs against MM. In vitro, we found that g-NK cells have strikingly superior anti-myeloma cytotoxicity compared with conventional NK (cNK) cells when combined with daratumumab or elotuzumab (∼sixfold; P < .001). In addition, g-NK cells naturally expressed minimal surface CD38 and SLAMF7, which reduced the incidence of therapeutic fratricide. In tumor-naïve murine models, the persistence of g-NK cells in blood and spleen was >10 times higher than that of cNK cells over 31 days (P < .001). In vivo efficacy studies showed that the combination of daratumumab and g-NK cells led to a >99.9% tumor reduction (by flow cytometry analysis) compared with the combination of daratumumab and cNK cells (P < .001). Moreover, treatment with daratumumab and g-NK cells led to complete elimination of myeloma burden in 5 of 7 mice. Collectively, these results underscore the unique ability of g-NK cells to potentiate the activity of therapeutic mAbs and overcome limitations of current off-the-shelf NK cell therapies without the need for cellular irradiation or genetic engineering.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bigley AB, Spade S, Agha NH, et al. FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma. Blood Adv. 2021. PMID: 34357379. doi:10.1182/bloodadvances.2020002440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。